Zobrazeno 1 - 10
of 166
pro vyhledávání: '"M. Halldin"'
Autor:
Märta Dahlström, Nather Madjid, Gunnar Nordvall, Magnus M. Halldin, Erika Vazquez-Juarez, Maria Lindskog, Johan Sandin, Bengt Winblad, Maria Eriksdotter, Pontus Forsell
Publikováno v:
Cells, Vol 10, Iss 8, p 1871 (2021)
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and results in severe neurodegeneration and progressive cognitive decline. Neurotrophins are growth factors involved in the development and survival of neurons, but also in unde
Externí odkaz:
https://doaj.org/article/b331350bd50e46729a55824ad315d585
Publikováno v:
European Journal of Pain. 23:1767-1779
Background Three TRPV1 (Transient Receptor Potential Vanilloid Receptor 1) antagonists were developed for testing in situ in human skin (Sjogren et al., 2016; Sjogren et al., 2018; Sjogren et al., 2018). The first human study using these compounds an
Autor:
Johan Sandin, Erika Vázquez-Juárez, Magnus M. Halldin, Gunnar Nordvall, Märta Dahlström, Maria Lindskog, Maria Eriksdotter, Pontus Forsell, Bengt Winblad, Nather Madjid
Publikováno v:
Cells
Volume 10
Issue 8
Cells, Vol 10, Iss 1871, p 1871 (2021)
Volume 10
Issue 8
Cells, Vol 10, Iss 1871, p 1871 (2021)
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and results in severe neurodegeneration and progressive cognitive decline. Neurotrophins are growth factors involved in the development and survival of neurons, but also in unde
Autor:
J. Sandin, G. Nordvall, M. Dahlström, C. Parrado, M. Backlund, V. Lidell, M. Halldin, P. Forsell
Publikováno v:
European Neuropsychopharmacology. 53:S166-S167
Publikováno v:
European Journal of Pain. 22:889-903
The transient receptor potential vanilloid receptor 1 (TRPV1) is a nonselective cation channel involved in the mediation of peripheral pain to the central nervous system. As such, the TRPV1 is an accessible molecular target that lends itself well to
Autor:
T. Kullenberg, Anna K. Sundgren-Andersson, Märta Segerdahl, O. Stålberg, Magnus M. Halldin, B. Jonzon, Erik Sjögren
Publikováno v:
European journal of pain (London, England). 22(7)
Background The transient receptor potential cation channel subfamily V 1 (TRPV1) is involved in nociception and has thus been of interest for drug developers, as a target for novel analgesics. However, several oral TRPV1 antagonists have failed in de
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jan Gustafsson, Anna Nordenström, M. Halldin Stenlid, S. Ask, U. von Döbeln, C. Bieneck Haglind
Publikováno v:
Journal of Inherited Metabolic Disease. 38:315-322
Children with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD) have a defect in the degradation of long-chain fatty acids and are at risk of hypoketotic hypoglycemia and insufficient energy production as well as accumulation of toxic fat
Autor:
Göran Eklund, Magnus M. Halldin, Åsa Brunnström, Antti Kautiainen, Anna Sandholm, Johanna Haglund, Suzanne L. Iverson
Publikováno v:
Chemical Research in Toxicology. 27:601-610
The recent stream of regulatory guidelines on the Safety Testing of Drug Metabolites by the FDA in 2008 and the ICH in 2009 and 2012 has cast light on the importance of qualifying metabolite exposure as part of the safety evaluation of new drugs and
Autor:
Erik Sjögren, Magnus M. Halldin, Anna K. Sundgren-Andersson, Sara B. E. Andersson, Olle Stålberg
Publikováno v:
Journal of pharmaceutical sciences. 105(9)
Cyclodextrins (CD) have the ability to form inclusion complexes with drugs and can be used as excipients to enhance solubility of poorly soluble drugs. To make accurate estimations of the potency of the drug, knowledge of the free drug concentration